PubMed · 2020 · 44 citations · 43 references
Open access
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyMolecular OncologyBreast Cancer PharmacotherapyChemotherapy ResistanceMetastatic Breast CancerTargeted Cancer TherapyTargeted TherapyTherapeutic ResistanceMetastatic Breast Cancer TreatmentOlaparib TherapyParp InhibitionParp Inhibitor ResistancePoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase InhibitionPoly(adp-ribose) Polymerase InhibitorsTherapeutic Failure
mutations. Despite impressive response rates of ~60%, the prolongation in median progression-free survival with a PARPi is modest, suggesting the emergence of resistance. Several studies have reported that receptor tyrosine kinases (RTKs), such as c-MET (also known as hepatocyte growth factor receptor), are involved in resistance to various anti-neoplastic agents, including PARPi. However, the mechanism by which c-MET contributes to acquired resistance to PARPi in TNBC is not fully understood. In this study, we show that hyperactivated c-Met is detected in TNBC cells with acquired resistance to PARPi, and the combination of talazoparib and crizotinib (a multi-kinase inhibitor that inhibits c-MET) synergistically inhibits proliferation in these cells. Unexpectedly, depleting c-MET had limited effect on talazoparib sensitivity in PARPi-resistant cells. Interestingly, we found evidence of epidermal growth factor receptor (EGFR) hyperactivation and interaction of EGFR/c-Met in these cells. Notably, combining EGFR and PARP inhibitors resulted in greater inhibition of proliferation in c-MET-depleted TNBC cells, and combined c-MET and EGFR inhibition increased sensitivity to talazoparib in TNBC cells with acquired resistance to PARPi. Our findings suggest that combined inhibition of c-MET and EGFR could potentially re-sensitize TNBC to the cytotoxic effects of PARPi.
43
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text
Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +16
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Lisa A. Carey, Elizabeth Claire Dees, Lynda Sawyer et al. · Clinical Cancer Research · 2007 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +14